For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 weeks in adults with overweight or obesity and without diabetes, according ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Her doctor was on board, so long as Hasan also agreed to start resistance training—something she had only done briefly in the ...

MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025.

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Juleen R. Zierath, Ph.D. - Professor of Clinical Integrative Physiology at Karolinska Institutet, Stockholm, Sweden, and Professor of Integrative Physiology and Executive Director at the Novo Nordisk ...

MBX Biosciences (MBX) announced positive results from its Phase 1 single ascending dose, SAD, and multiple ascending dose, MAD, clinical trial ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.